Angle Share Discussion Threads

[seagreen] 09/1/2024 11:54

Or you can ignore the shorter and listen to the analysts who know the company inside out.

[banshee] 09/1/2024 11:46

Here is just one early quoted example from the paper I cited Outsize there are many more in it if you can bothered to look and it's just one paper, there are other co's and papers more coming through all time time.





" ISET technology allows the isolation of CTCs without any specific epithelial surface markers antibodies
Application for all solid tumors
High sensibility: Detection threshold of one CTC per 10 ml of blood
Isolation of CTCs and cfDNA simultaneously from the same sample
Specific ISET buffers for live and fixed cells application to preserve structural cells integrity
Compatibility with downstream processing from cytology analysis to DNA gene mutation detection
ISET® Device is CE IVD
Large scientific literature backup

DYOR

[lawson27] 09/1/2024 11:44

Surely a take-over target, i'm in for the ride, GLA

[havinthelasttoast] 09/1/2024 11:34

Don’t be fooled. Pump and dump

[bloomberg2] 09/1/2024 11:33

https://youtu.be/T84dax2MDPg?feature=shared

[outsizeclothes.com] 09/1/2024 11:27

Banshee - re:- the large amount of competition.
Can you please answer my question from last week ?
As someone who spouts about the large amount of competition - give me an answer !
Which Companies can now, commercially, extract CTCs that are unmarked, living, undamaged and viable for analysis for DNA / protein signatures ?

JUST LIST THEM BY NAME.

( & don't point to some research paper that lists technology that's not even developed yet as competition )

[banshee] 09/1/2024 11:24

As an alternatively to watching the company video you could email or even speak to some of the real world end users who will give a different picture, if reading the objective scientific papers is too much like hard work.

The reality is well known to long term holders here (or should be), but for obvious reasons they prefer to ignore it, just as the company prefers to discreetly not reference it

All Imo DYOR.

[bloomberg2] 09/1/2024 11:24

Has to be RNS first !!

[stevehuges] 09/1/2024 11:22

Over on lse site someone saying 2 commercial deals will be announced on mornings of the presentation. Hay don't shoot messenger

[sicilian_kan] 09/1/2024 11:14

Thanks boris.

On the subject of what is required to run a sample through Parsortix, this video from Angle is worth watching.

[boris cobaka] 09/1/2024 11:02

Thanks for clarifying SK

[seagreen] 09/1/2024 11:00

(Plus the king and queen of the ENET ramp who sold early and lost out)

[sawney] 09/1/2024 10:59

Your altruism knows no bounds....:-)

[seagreen] 09/1/2024 10:59

classic 33% pull back before hopefully starting the next leg up...best to read the analysts views not people who are talking their own short book who have consistantly posted negative views (circa 30 posts including weekend) since the spike and not posted on any other thread for a while. imho.

[arab3] 09/1/2024 10:50

What other shares do you hold banshee ?

[banshee] 09/1/2024 10:47

The importance of how long parsortix takes to process a blood sample (it can only do one at a time) is a critical reality check to dreams of world domination, as is the amount of manual intervention required to process a sample and the large amount of competition.

AGL always used to quote a realistic real world 1-2 samples a day, but appreciative of the the fact that this would have shareholders running for the hills imo, they now seem present a different claim on their website. You can run blood through the system as fast as you like but accuracy and ctc capture will fall of a cliff as ctcs are forced through the traps designed to catch them, that is what allows them to make these disingenuous claims imo, their end customers are experienced scientists well aware of the reality.

AGL have never released an RNS saying Parsortix has speeded up its processing, because this has not happend, had it done so they would have been RNS'ing right left and centre.

You can find an objective assessment in this, peer reviewed, non-hyping scientific paper reviewing the various different techs available and their pro's and cons. I urge all those swallowing the pre fund raising hype to read it. Do not take your info from the company website.



"The Parsortix (Angle) device has been developed with a chip containing a stepped/gradiated separation structure that gradually decreases with size, with final gap sizes ranging from 4.5 μm to 10 μm. The most common GEN3D6.5 Cell Separation Cassette has a “critical gapâ€� size of 6.5 µm which acts to capture larger CTCs and allows other smaller, more deformable blood components to pass through [113]. The device is fairly slow at processing, taking ~4 h for 7.5 mL blood and is only semi-automated, requiring significant user input. Following cell capture, a reverse pressure is then applied to harvest the CTCs. The device is able to capture CTC clusters and there is the option for on-chip staining, however on chip imaging is difficult. Using the 6.5 µm gap size cassette, an average capture rate of 62.4% was achieved across breast- and NSCLC-derived cell lines, however purity decreases as the cassette “critical gapâ€� size decreases [35]. The system is well suited to enrich CTCs from clinical samples (although harvested cells are not pure CTCs), taking advantage of the different physical properties (i.e., size and deformability) of the target rare cells compared to other blood components such as RBCs and WBCs."

AGL ALWAYS raise new funds at least 6-9 months before the existing cash runs out, check their numerous previous fund raisings. This latest wildly hyping RNS is about rebasing the share price and sucking in a few more gullible institutions to fork up another 30 million or so IMO.

The reality of 11 Years of aggressive marketing hype and spin resulting in 2.3million in sales is not enough to get them anywhere, so they have to be creative.

All imo DYOR and read the objective scientifc papers . See if you still beleive the hype when yoiu have done it.

[sicilian_kan] 09/1/2024 10:42

This is factually inaccurate from the post a few above:

"- 2023 Revenue up 120%

- 2024 Revenue expected to treble (not including any new deals)"

This would take 2024 revenue to about £6m if met...however...

The trading update RNS on 9 November stated "New sales secured in 2023 are expected to be c. £3.3 million however revenue recognition for some of these sales will fall into the 2024 financial year."

So clearly when Angle states "Revenue recognised for 2024 expected to treble compared to 2023" that is totally and utterly dependent upon new deals.

[g2theary] 09/1/2024 10:40

Ha so you were wrong yesterday then when I was buying more for that 36p top again ;) that's coming this afternoon Vauxhall :D

[gurunostradamus] 09/1/2024 10:37

Volume seems high early this morning, 50000 buyer seems to be back.

[astra1vision] 09/1/2024 10:28

ZEUS and SEBALL still trying to keep disciples interested. Really quite sad.

[g2theary] 09/1/2024 10:13

Here we go ;)

[stevehuges] 09/1/2024 10:08

Flood gates have opened boys and girls

[sawney] 09/1/2024 09:54

Boris...
Admittance time...as it happens, I sold a few on Thursday after averaging down...

Still currently underwater at around 50p....but a lot happier than I was this time last year..

ATB

[smraynot] 09/1/2024 09:50

Have a look at BANK! New licence rumours!🚀